Abiopharma

🔍 BEKKE NATHAN E. (Executive)

Company: LEE ENTERPRISES, Inc (LEE)

Report Date: 2026-08-06

Detailed Transactions and Holdings:

• Acquired 107,759 shares of Common Stock (Direct)
  Date: 2026-08-06 | Code: A | equity_swap_involved: 0 | shares_owned_after: 143,696.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 5,946 shares of Employee Stock Option (Right to Buy) at $16.36 per share (Derivative)
  Date: 2025-03-11 | Code: A | Expires: 2034-12-15 | equity_swap_involved: 0 | shares_owned_after: 5,946.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 7,273 shares of Performance Rights (Derivative)
  Date: 2025-03-11 | Code: A | Expires: 2027-09-26 | equity_swap_involved: 0 | shares_owned_after: 7,273.00 | transaction_form_type: 4 | Footnotes: F3, F1, F3
• Acquired 107,759 shares of Performance Rights (Derivative)
  Date: 2026-08-06 | Code: A | Expires: 2029-09-30 | equity_swap_involved: 0 | shares_owned_after: 107,759.00 | transaction_form_type: 4 | Footnotes: F3, F1, F3

Footnotes:

• F1: The grant of restricted stock awards, stock options, and performance shares were approved by the executive compensation committee of LEE's board of directors on December 16, 2024, subject to shareholder approval of the First Amendment to the 2020 Long-Term Incentive Plan ("Amendment") under which the awards were granted and the subsequent filing of LEE's Registration Statement on Form S-8 registering the additional shares authorized under the Amendment. LEE's shareholders approved the Amendment on February 27, 2025, and the Form S-8 was filed with the Securities and Exchange Commission on March 11, 2025.
• F2: The option vests in three equal annual installments beginning on December 16, 2025.
• F3: Each performance right represents a contingent right to receive one share of LEE common stock. The performance rights vest on the expiration date and upon the satisfaction of certain performance criteria of LEE's common stock.